RESPeRATE’s safety & efficacy was demonstrated in
50+ published clinical trials.
Home Systolic Blood Pressure Change (% of 8 wk reduction) 
RESPeRATE safety and efficacy in lowering blood pressure were demonstrated repeatedly in 19 separate clinical research studies published in peer-reviewed medical journals [2-19]
RESPeRATE delivers a significant, all-day long, sustained reduction in blood pressure, when measured at the office [2-19], at home [3-7, 9, 12-13] and even with 24-hour Ambulatory Blood Pressure Monitor [4, 10, 18].
RESPeRATE’s clinical evidence won it the world’s only FDA clearance for non-drug treatment of hypertension.
Improved sleep was the only “side effect” reported by over 250,000 patients and doctors in the past 15 years.
American Heart Association Scientific Statement Brook RC et al. 2013;61(6):1360-1383.
Learn More >>
Device-Guided Slow Breathing - Summary and Clinical Recommendations
See AHA full Statement here
“The overall evidence from clinical trials and meta-analyses suggests that device-guided slow breathing can significantly lower BP. There are no known
contraindications to the use of the device, and no adverse effects have been noted. Unfortunately, the device currently costs in excess of $200 in
the United States; however, it has recently been included on the British National Health Service’s Drug Tariff (Part IX), which makes its cost reimbursable
if prescribed by a physician. Specific recommendations for use are outlined elsewhere and by the manufacturer (http://www.resperate.com). Another limitation is
that device-guided slow breathing has not been directly compared with other forms of regulated breathing such as pranayama. Hence, it remains unknown whether paced
slow breathing can be taught and effectively used to lower BP over the long term without the use of a device. According to trial evidence, 15-minute sessions of
device-guided slow breathing need to be performed at least 3 to 4 times per week to reduce BP. It has been suggested that more frequent use may lead to greater
BP lowering; however further evidence is required in this regard. There have been no trials longer than 8 to 9 weeks’ duration; hence, the efficacy of long term
use is unclear. Longer and larger studies are also required to demonstrate the patient populations most likely to benefit from this technology.[88,89,110,111]
The writing group conferred to device-guided breathing a Class IIA, Level of Evidence B recommendation for BP-lowering efficacy. Device-guided breathing is
reasonable to perform in clinical practice to reduce BP. Should additional studies in larger and broader populations corroborate its effectiveness thus far
demonstrated, it is conceivable that this technique may merit even stronger recommendations in the future.”
Please note: American Heart Association does not specifically recommend or endorse use of any products provided by RESPeRATE.
RESPeRATE was found safe and effective in populations ranging from healthy normotensive  to refractory hypertensives .
The studies performed in the US, Europe, Middle East, and the Far East also found it was effective in patients with comorbidities as diabetes [9, 11, 18], chronic kidney failure , pulmonary arterial hypertension , CHF [23, 32-39], COPD  and more.
Weighted average from the studies was 10/5 mmHg sustained office BP reduction in adults both with controlled and uncontrolled BP.
BP reductions were independent of gender and medication status.
Studies [2-8,10-11] showed that patients over 65 saw greater BP reductions averaging 16/7 mmHg.
They also demonstrated that patients with stage 2 hypertension (systolic BP>160 mmHg) saw larger reductions averaging 17/7 mmHg.
The randomized controlled study  that won RESPeRATE it’s FDA-clearance for use without a prescription (OTC) demonstrated that slow breathing was the “active component” and a “dose-response.”
Using RESPeRATE for only 45 minutes a week of slow breathing delivers significant blood pressure reductions.
Using RESPeRATE more yields an even larger reduction.
Eight studies demonstrated the physiological mechanism of action behind RESPeRATE effects. See the scheme in the medical textbook Hypertension Primer .
The studies demonstrated that RESPeRATE delivers an acute reduction of the sympathetic neural activity [22, 23, 25-27], resulting among other things in a sustained decrease in peripheral resistance and arterial stiffness [28-30].
Beyond the 19 clinical studies in hypertension, independent researchers around the world have published more than 30 additional clinical studies demonstrating the various cardiopulmonary and neurological benefits of RESPeRATE.
Enclosed is a breakdown of some of published clinical studies demonstrating that RESPeRATE might be beneficial in the following conditions:
Please note that RESPeRATE has been cleared for marketing only for lowering blood pressure and stress.
$65 FREE Extras. Ends Soon.
Add To Cart >>
Risk-free Order:60 day money back guarantee
Risk-free Order: 60 day money back guarantee
A one-time payment of $349.95 or pay in 4 interest-free installments of
87.49 + Free S&H
Pay in 4 interest-free installments so you can spread the cost.
See payment terms. A higher initial payment may be required for some consumers. CA residents: Loans made or arranged pursuant to a California Financing Law license.